Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Dapagliflozin · Farxiga

Small molecule · Inhibitor of sodium-glucose cotransporter 2 (SLC5A2) · developed by Astrazeneca

Approved FDA, Jan 2014
AZN Developer

What is Dapagliflozin?

Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that acts in the proximal renal tubules to reduce glucose reabsorption, promoting urinary glucose excretion, and also reduces sodium reabsorption.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Farxiga
Drug type
Small molecule
Targets
sodium-glucose cotransporter 2 (SLC5A2)
Mechanism
Inhibitor of sodium-glucose cotransporter 2 (SLC5A2)
Pathways
renal glucose reabsorption, renal sodium reabsorption, tubuloglomerular feedback
Therapy area
Renal & urology
Developer
Astrazeneca Ab (AZN)
FDA status
Approved as Farxiga (January 8, 2014), NDA202293 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 10, 2026). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Chronic Kidney Disease

Other drugs acting on SLC5A2

More from Astrazeneca

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Dapagliflozin

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.